Natco Pharma net profit jumps 83 percent to Rs 676 crore in Q2

Published On 2024-11-13 11:51 GMT   |   Update On 2024-11-13 11:51 GMT
Advertisement

Natco Pharma has announced an 83 percent on-year increase in its consolidated net profit for the September 2024 quarter, which rose to Rs 676 crore, driven by strong sales performance. In the July-September period of the previous fiscal, the company had reported a net profit of Rs 369 crore. 

Revenue from operations rose to Rs 1,371 crore as compared with Rs 1,031 crore in the year-ago period, Natco Pharma said in a regulatory filing.

Advertisement

"The company has shown continued strong growth during the second quarter driven by exports formulation business and stable domestic pharmaceutical business," it stated according to PTI.

Natco Pharma's board has declared a second interim dividend of Rs 1.5 per equity share of Rs 2 each for financial year 2024-25.

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 employees, Natco today has eight manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc. 

Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News